BTIG downgraded Zimmer Biomet (NYSE: ZBH) to Neutral from Buy and withdrew its $112 price target, citing limited upside potential in the near term. The firm noted that fiscal 2025 was a challenging year for the company, with shares declining 14.8% despite efforts to improve both growth and profitability. BTIG said that recently launched products, including the so-called “Magnificent 7,” did not significantly accelerate organic growth during 2025, while Paragon 28 also underperformed expectations. The downgr ...